$NKTR
NEKTAR THERAPEUTICS Stock $nktr

$nktr Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000119312513433110 Filed on November 07, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	$31.15M	$60.91M	$18.41M
YoY Change	47.29%	230.81%	-31.98%
Cost Of Revenue	$8.960M	$12.88M	$7.228M
YoY Change	22.91%	78.15%	43.47%
Gross Profit	$22.19M	$48.03M	$11.18M
YoY Change	60.12%	329.47%	-49.23%
Gross Profit Margin	71.23%	78.86%	60.74%
Selling, General & Admin	$9.800M	$10.60M	$10.10M
YoY Change	-10.09%	4.95%	-18.55%
% of Gross Profit	44.17%	22.07%	90.31%
Research & Development	$48.25M	$43.91M	$34.02M
YoY Change	4.04%	29.1%	9.67%
% of Gross Profit	217.47%	91.43%	304.15%
Depreciation & Amortization	$3.400M	$3.600M	$3.600M
YoY Change	-12.82%	0.0%	-5.26%
% of Gross Profit	15.32%	7.5%	32.19%
Operating Expenses	$48.25M	$43.91M	$34.02M
YoY Change	4.04%	29.1%	9.67%
Operating Profit	-$35.89M	-$6.525M	-$32.90M
YoY Change	-17.26%	-80.17%	54.19%
Interest Expense	-$10.10M	$4.587M	$5.697M
YoY Change	5.21%	-19.48%	124.03%
% of Operating Profit
Other Income/Expense, Net		-$9.825M	-$10.43M
YoY Change		-5.76%	295.19%
Pretax Income	-$46.00M	-$16.35M	-$43.33M
YoY Change	-13.21%	-62.26%	80.7%
Income Tax	$1.600M	$193.0K	$222.0K
% Of Pretax Income
Net Earnings	-$47.66M	-$16.54M	-$43.55M
YoY Change	-9.95%	-62.01%	80.93%
Net Earnings / Revenue	-153.02%	-27.16%	-236.51%
Basic Earnings Per Share	-$0.41	-$0.14
Diluted Earnings Per Share	-$0.41	-$0.14	-$378.6K
COMMON SHARES
Basic Shares Outstanding	116.1M shares	115.8M shares
Diluted Shares Outstanding		115.8M shares

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$237.0M	$183.6M	$319.3M
YoY Change	-14.5%	-42.5%	19.81%
Cash & Equivalents	$39.07M	$65.41M	$10.34M
Short-Term Investments	$198.0M	$118.1M	$308.9M
Other Short-Term Assets	$5.175M	$4.759M	$7.003M
YoY Change	-61.27%	-32.04%	-7.86%
Inventory	$13.45M	$15.08M	$16.75M
Prepaid Expenses
Receivables	$2.229M	$4.557M	$3.911M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$257.9M	$207.9M	$346.9M
YoY Change	-18.04%	-40.06%	16.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$66.97M	$65.08M	$73.26M
YoY Change	-7.26%	-11.16%	-10.23%
Goodwill	$76.50M	$76.50M	$76.50M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments			$35.00M
YoY Change			-81.72%
Other Assets	$8.170M	$8.510M	$9.728M
YoY Change	-13.48%	-12.52%	1116.0%
Total Long-Term Assets	$176.6M	$175.1M	$194.5M
YoY Change	-3.56%	-9.98%	-44.51%
TOTAL ASSETS
Total Short-Term Assets	$257.9M	$207.9M	$346.9M
Total Long-Term Assets	$176.6M	$175.1M	$194.5M
Total Assets	$434.5M	$383.0M	$541.5M
YoY Change	-12.71%	-29.26%	-16.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.115M	$3.723M	$2.624M
YoY Change	218.37%	41.88%	19.27%
Accrued Expenses	$6.243M	$10.77M	$6.450M
YoY Change	-22.04%	66.99%	-82.61%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$98.22M	$80.91M	$69.47M
YoY Change	25.06%	16.47%	-75.1%
LONG-TERM LIABILITIES
Long-Term Debt	$203.0M	$134.0M	$264.2M
YoY Change	48.61%	-49.28%	1626.8%
Other Long-Term Liabilities	$19.26M	$9.217M	$10.73M
YoY Change	78.11%	-14.08%	-91.28%
Total Long-Term Liabilities	$19.26M	$9.217M	$10.73M
YoY Change	78.11%	-14.08%	-92.24%
TOTAL LIABILITIES
Total Short-Term Liabilities	$98.22M	$80.91M	$69.47M
Total Long-Term Liabilities	$19.26M	$9.217M	$10.73M
Total Liabilities	$524.4M	$433.3M	$446.1M
YoY Change	16.34%	-2.88%	6.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.732B	-$1.685B	-$1.517B
YoY Change	10.32%	11.02%
Common Stock	$1.644B	$1.636B	$1.613B
YoY Change	1.6%	1.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$89.90M	-$50.25M	$95.33M
YoY Change
Total Liabilities & Shareholders Equity	$434.5M	$383.0M	$541.5M
YoY Change	-12.71%	-29.26%	-16.46%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$47.66M	-$16.54M	-$43.55M
YoY Change	-9.95%	-62.01%	80.93%
Depreciation, Depletion And Amortization	$3.400M	$3.600M	$3.600M
YoY Change	-12.82%	0.0%	-5.26%
Cash From Operating Activities	$53.70M	-$19.80M	-$27.20M
YoY Change	-213.29%	-27.21%	24.77%
INVESTING ACTIVITIES
Capital Expenditures	-$2.700M	-$600.0K	-$2.500M
YoY Change	-44.9%	-76.0%	66.67%
Acquisitions
YoY Change
Other Investing Activities	-$79.40M	$42.30M	-$2.900M
YoY Change	-218.33%	-1558.62%	-105.36%
Cash From Investing Activities	-$82.20M	$41.80M	-$5.400M
YoY Change	-232.15%	-874.07%	-110.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.100M	1.900M	-93.20M
YoY Change	950.0%	-102.04%
NET CHANGE
Cash From Operating Activities	53.70M	-19.80M	-27.20M
Cash From Investing Activities	-82.20M	41.80M	-5.400M
Cash From Financing Activities	2.100M	1.900M	-93.20M
Net Change In Cash	-26.40M	23.90M	-125.8M
YoY Change	-276.0%	-119.0%	-507.12%
FREE CASH FLOW
Cash From Operating Activities	$53.70M	-$19.80M	-$27.20M
Capital Expenditures	-$2.700M	-$600.0K	-$2.500M
Free Cash Flow	$56.40M	-$19.20M	-$24.70M
YoY Change	-232.71%	-22.27%	21.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	116115377	shares
CY2012Q3	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2012Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10338000
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	115990000	shares
CY2013Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.12	pure
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	115990000	shares
CY2013Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2013Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10771000
CY2013Q3	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3723000
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	80913000
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1689000
CY2013Q3	us-gaap	Senior Long Term Notes SeniorLongTermNotes	125000000
CY2013Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	13910000
CY2013Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9217000
CY2013Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	9007000
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	-50250000
CY2013Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1636162000
CY2013Q3	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	147600000
CY2013Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1684734000
CY2013Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	21300000
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	11000
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	383035000
CY2013Q3	us-gaap	Liabilities Liabilities	433285000
CY2013Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	12803000
CY2013Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	82233000
CY2013Q3	us-gaap	Interest Payable Current InterestPayableCurrent	3167000
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q3	us-gaap	Other Deferred Credits Noncurrent OtherDeferredCreditsNoncurrent	1748000
CY2013Q3	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	25000000
CY2013Q3	us-gaap	Assets Current AssetsCurrent	207942000
CY2013Q3	us-gaap	Goodwill Goodwill	76501000
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8510000
CY2013Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	118139000
CY2013Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	8638000
CY2013Q3	us-gaap	Assets Assets	383035000
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65411000
CY2013Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	4913000
CY2013Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4557000
CY2013Q3	us-gaap	Inventory Net InventoryNet	15076000
CY2013Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	121938000
CY2013Q3	us-gaap	Other Assets Current OtherAssetsCurrent	4759000
CY2013Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1525000
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65082000
CY2013Q3	nktr	Debt Instrument Maturity Month And Year DebtInstrumentMaturityMonthAndYear	2017-07
CY2013Q3	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	125167000
CY2013Q3	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2013Q3	nktr	Cash And Restricted Cash CashAndRestrictedCash	27861000
CY2013Q3	nktr	License And Collaboration Agreements Potential Payments For Development Milestones LicenseAndCollaborationAgreementsPotentialPaymentsForDevelopmentMilestones	144300000
CY2013Q3	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	208550000
CY2013Q3	nktr	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	15239000
CY2013Q3	nktr	Accrued Contingent Liability And Interest AccruedContingentLiabilityAndInterest	3000000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15312000
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	115259000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	115259000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8008000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2863000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	78537000
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-357000
CY2012Q4	us-gaap	Senior Long Term Notes SeniorLongTermNotes	125000000
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8773000
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8407000
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	11607000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	47018000
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1617744000
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1570380000
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	21896000
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	11000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	497790000
CY2012Q4	us-gaap	Liabilities Liabilities	450772000
CY2012Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	12414000
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	96551000
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	7083000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Other Deferred Credits Noncurrent OtherDeferredCreditsNoncurrent	2404000
CY2012Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	25000000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	314631000
CY2012Q4	us-gaap	Goodwill Goodwill	76501000
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9443000
CY2012Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	251757000
CY2012Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	6661000
CY2012Q4	us-gaap	Assets Assets	497790000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25437000
CY2012Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	7489000
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5805000
CY2012Q4	us-gaap	Inventory Net InventoryNet	18269000
CY2012Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	252760000
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	13363000
CY2012Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4119000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	72215000
CY2012Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	128266000
CY2012Q4	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2012Q4	nktr	Cash And Restricted Cash CashAndRestrictedCash	26947000
CY2012Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	302194000
CY2012Q4	nktr	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	17500000
	dei	Trading Symbol TradingSymbol	NKTR
	dei	Entity Registrant Name EntityRegistrantName	NEKTAR THERAPEUTICS
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Entity Central Index Key EntityCentralIndexKey	0000906709
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.34	pure
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b><i>Reclassifications</i></b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders’ equity.</p> </div>
	us-gaap	Costs And Expenses CostsAndExpenses	202011000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	5137000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30700000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	39974000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2741000
	us-gaap	Interest Expense InterestExpense	13888000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	697000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	115557000	shares
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-92158000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.99
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1382000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	132060000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	141762000
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-4825000
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates and assumptions. On an ongoing basis, we evaluate our estimates, including those related to deferred revenue recognition periods, inventories, the impairment of investments, the impairment of goodwill and long-lived assets, contingencies, accrued clinical trial expenses, estimated interest expense from our liability related to our sale of future royalties, stock-based compensation, and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.</p> </div>
	us-gaap	Revenues Revenues	117775000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-115686000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	140569000
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	36806000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	385000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	639000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-6817000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-332000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-84236000
	us-gaap	Interest Paid InterestPaid	17097000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-113744000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1248000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-29508000
	us-gaap	Net Income Loss NetIncomeLoss	-114354000
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	2201000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3193000
	us-gaap	Royalty Revenue RoyaltyRevenue	1030000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	52000
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	29549000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-14914000
	us-gaap	Share Based Compensation ShareBasedCompensation	13165000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10882000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	5253000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	274011000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-3916000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	610000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	20000
	nktr	Debt Instrument Maximum Maturity Period DebtInstrumentMaximumMaturityPeriod	Two years or less
	nktr	Increase Decrease In Accrued Clinical Trial Expenses IncreaseDecreaseInAccruedClinicalTrialExpenses	-2261000
	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	67195000
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	12744000
	nktr	Debt Instrument Weighted Average Maturity Period One DebtInstrumentWeightedAverageMaturityPeriodOne	One year or less
	nktr	Noncash Interest Expense NoncashInterestExpense	16644000
	nktr	Estimated Annual Interest Rate On Royalty Liability EstimatedAnnualInterestRateOnRoyaltyLiability	0.17	pure
	nktr	Repayment Of And Proceeds From Sale Of Future Royalties Net Of Transaction Costs RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts	-3000000
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.32	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	114699000	shares
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-82380000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.04
	us-gaap	Revenues Revenues	60045000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-117671000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	126609000
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	24994000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	913000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4400000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1865000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-10593000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-641000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-97820000
	us-gaap	Available For Sale Securities Gross Realized Gains Losses Sale Proceeds AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds	5400000
	us-gaap	Interest Paid InterestPaid	9010000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-118490000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1027000
	us-gaap	Repayments Of Subordinated Debt RepaymentsOfSubordinatedDebt	172407000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-20670000
	us-gaap	Net Income Loss NetIncomeLoss	-118929000
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1773000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4098000
	us-gaap	Royalty Revenue RoyaltyRevenue	3966000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5744000
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	42548000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	25000000
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1675000
	us-gaap	Costs And Expenses CostsAndExpenses	157865000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-120000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30750000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26591000
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	78006000
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	23138000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3430000
	us-gaap	Share Based Compensation ShareBasedCompensation	12015000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10810000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4974000
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	5378000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-465000
	us-gaap	Interest Expense InterestExpense	10807000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-401000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	50793000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	102302000
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-219000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	3177000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	202768000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1528000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	439000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	22000
	nktr	Increase Decrease In Accrued Clinical Trial Expenses IncreaseDecreaseInAccruedClinicalTrialExpenses	1247000
	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	24190000
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	6895000
	nktr	Transaction Costs Related To Sale Of Potential Future Royalties TransactionCostsRelatedToSaleOfPotentialFutureRoyalties	4400000
	nktr	Noncash Interest Expense NoncashInterestExpense	12641000
	nktr	Repayment Of And Proceeds From Sale Of Future Royalties Net Of Transaction Costs RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts	119588000
CY2012Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.32	pure
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	114915000	shares
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2012Q3	us-gaap	Revenues Revenues	18412000
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42772000
CY2012Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	8355000
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	156000
CY2012Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	603000
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-32900000
CY2012Q3	us-gaap	Available For Sale Securities Gross Realized Gains Losses Sale Proceeds AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds	5400000
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-43325000
CY2012Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10425000
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-43547000
CY2012Q3	us-gaap	Royalty Revenue RoyaltyRevenue	498000
CY2012Q3	us-gaap	Costs And Expenses CostsAndExpenses	51312000
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10068000
CY2012Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	7228000
CY2012Q3	us-gaap	Share Based Compensation ShareBasedCompensation	3980000
CY2012Q3	us-gaap	Interest Expense InterestExpense	5697000
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34016000
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	222000
CY2012Q3	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	6132000
CY2012Q3	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	3427000
CY2012Q3	nktr	Noncash Interest Expense NoncashInterestExpense	5487000
CY2013Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.34	pure
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	115812000	shares
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2013Q3	us-gaap	Revenues Revenues	60909000
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16896000
CY2013Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	14672000
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	262000
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	116000
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6525000
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16350000
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9825000
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-16543000
CY2013Q3	us-gaap	Royalty Revenue RoyaltyRevenue	354000
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	67434000
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10643000
CY2013Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	12877000
CY2013Q3	us-gaap	Share Based Compensation ShareBasedCompensation	4564000
CY2013Q3	us-gaap	Interest Expense InterestExpense	4587000
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43914000
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	193000
CY2013Q3	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	41360000
CY2013Q3	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	4523000
CY2013Q3	nktr	Noncash Interest Expense NoncashInterestExpense	5616000

Files In Submission

Name	View Source	Status
0001193125-13-433110-index-headers.html	Edgar Link	pending
0001193125-13-433110-index.html	Edgar Link	pending
0001193125-13-433110.txt	Edgar Link	pending
0001193125-13-433110-xbrl.zip	Edgar Link	pending
d594595d10q.htm	Edgar Link	pending
d594595dex101.htm	Edgar Link	pending
d594595dex311.htm	Edgar Link	pending
d594595dex312.htm	Edgar Link	pending
d594595dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
nktr-20130930.xml	Edgar Link	completed
nktr-20130930.xsd	Edgar Link	pending
nktr-20130930_cal.xml	Edgar Link	unprocessable
nktr-20130930_def.xml	Edgar Link	unprocessable
nktr-20130930_lab.xml	Edgar Link	unprocessable
nktr-20130930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NKTR
NEKTAR THERAPEUTICS Stock $nktr

2013 Q4 Form 10-Q Financial Statement

#000119312513433110 Filed on November 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR NEKTAR THERAPEUTICS Stock $nktr

2013 Q4 Form 10-Q Financial Statement

#000119312513433110 Filed on November 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR
NEKTAR THERAPEUTICS Stock $nktr